Worth Watching Stocks: Envestnet, Inc (NYSE:ENV) & IsoRay, Inc. (NYSE:ISR)

4

Envestnet, Inc (NYSE:ENV)

Envestnet, Inc. is an independent provider of technology-enabled, Web-based investment solutions and services to financial advisors. The Company’s technology platform allows financial advisors to provide their clients with a wide range of investment solutions and services. It offers risk assessment and selection of investment strategies, asset allocation models, research and due diligence, portfolio construction, proposal generation and paperwork preparation, model management and account rebalancing, account monitoring, customized fee billing, overlay services covering asset allocation, tax management and socially responsible investing, aggregated multi-custodian performance reporting and communication tools, as well as access to a range of third-party asset custodians. Envestnet focuses its technology development efforts and its sales and marketing approach on addressing financial advisors’ front, middle and back office needs. Envestnet, Inc. is headquartered in Chicago, Illinois.

Envestnet, Inc (NYSE:ENV)’s Financial Overview

Envestnet, Inc (NYSE) surged 2.34% yesterday to close its trading session at $55.96. The company has 1 year Price Target of $62. Envestnet, Inc has 52-Week high of $64.8 and 52-Week Low of $46.57. The stock touched its 52-Week High on 64.80 and 52-Week Low on 46.57. The stock traded with the volume of 184223 shares yesterday. The firm shows the market capitalization of $2.55 Billion.

Envestnet, Inc (NYSE) reported its last quarterly earnings on 9/29/2018 where the firm reported its Actual EPS of $0.53/share against the analyst consensus estimate of $0.5/share. The difference between the actual and expected EPS is $0.03 a share with a surprise factor of 6%.

The firm is trading with SMA20 of 4.69 Percent, SMA50 of 7.57 Percent and SMA200 of -0.36 percent. Envestnet, Inc has P/S value of 3.25 while its P/B value stands at 4.96. Similarly, the company has Return on Assets of 2.2 percent, Return on Equity of 4.9 percent and Return on Investment of 4.2 Percent. The company shows Gross Margin and Operating Margin of 67.7 percent and 2 percent respectively.

The Stock currently has Analyst’ mean Recommendation of 1.7 where the scale is from 1 to 5, 1 means Strong Buy and 5 means Sell.

The 11 analysts offering 12-month price forecasts for Envestnet Inc have a median target of 64.00, with a high estimate of 67.00 and a low estimate of 55.00. The median estimate represents a +14.37% increase from the last price of 55.96.

Envestnet, Inc is expected* to report earnings on 02/21/2019 after market close. The report will be for the fiscal Quarter ending Dec 2018. According to Zacks Investment Research, based on 4 analysts’ forecasts, the consensus EPS forecast for the quarter is $0.43. The reported EPS for the same quarter last year was $0.3.

IsoRay, Inc. (NYSE:ISR)

IsoRay, Inc. is a medical technology company that produces therapeutic radioactive isotopes. Through its subsidiary, IsoRay Medical, Inc., develops, manufactures and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases. The Company is engaged in the production and sales of Cesium-131 (Cs-131) brachytherapy seeds. Brachytherapy seeds are small devices containing a therapeutic dose of radiation used in an interstitial radiation procedure. The brachytherapy procedure places radioactive seeds as close as possible to (in or near) the cancerous tumor. The Cs-131 includes radioisotope in the treatment of all malignant tumors, such as prostate cancer, brain cancer, breast cancer, colorectal cancer, gynecological cancer, lung cancer, liver cancer, ocular melanoma and pancreatic cancer. The Company’s Proxcelan Cesium-131 seed is classified as a Class II device. The Company competes with Varian Medical Systems, Siemens Healthcare, Elekta AB and Accuray Incorporated.

IsoRay, Inc. (NYSE:ISR)’s Financial Outlook

The 2 analysts offering 12-month price forecasts for IsoRay Inc have a median target of 0.95, with a high estimate of 1.20 and a low estimate of 0.70. The median estimate represents a +108.79% increase from the last price of 0.46.

IsoRay, Inc. is expected* to report earnings on 02/12/2019 after market close. The report will be for the fiscal Quarter ending Dec 2018. According to Zacks Investment Research, based on 1 analysts’ forecasts, the consensus EPS forecast for the quarter is $-0.02. The reported EPS for the same quarter last year was $-0.03.

According to Zacks Investment Research, IsoRay, Inc. has a Consensus Recommendation of 2. (The Scale is from 1-5 where 1 means Strong Buy and 5 means Strong Sell).

The Stock surged 5.23% and closed its last trading session at $0.46. The company has the market capitalization of $30.19 Million. The stock has 52-week high of $1.22 and 52-Week low of $0.27. The firm touched its 52-Week high on 1.22 and 52-Week low on 0.27. The company has volume of 274619 shares. The company has a total of 66.36 Million shares outstanding.

IsoRay, Inc. (NYSE) in the last quarter reported its actual EPS of $-0.02/share where the analyst estimated EPS was $-0.02/share. The difference between the actual and Estimated EPS is $0. This shows a surprise factor of 0 percent.

The company has YTD performance of 51.67 percent. Beta for IsoRay, Inc. stands at 2.3 while its ATR (average true range) is 0.03. The company has Weekly Volatility of 5.85%% and Monthly Volatility of 7.12%%.

IsoRay, Inc. has distance from 20-day Simple Moving Average (SMA20) of 10.28%, Distance from 50-Day Simple Moving Average of 16.4 percent and Distance from 200-Day Simple Moving Average of -4.39%.

The Company currently has ROA (Return on Assets) of -69.3 percent, Return on Equity (ROE) of -87.2 Percent and Return on Investment (ROI) of -134.6% with Gross margin of 33.5 percent and Operating & Profit margin of 0% and 0% respectively.

SHARE